The Angiotensin Receptor Neprilysin Inhibitor LCZ696 in Heart Failure With Preserved Ejection Fraction: A Phase 2 Double-Blind Randomised Controlled Trial

Study Questions:

What is the safety and efficacy of LCZ696, a first-in-class angiotensin-receptor neprilysin inhibitor, in patients with heart failure with preserved ejection fraction (HFPEF)?